ATNM - Potential bottom reversal ロング

Actinium Pharmaceuticals, Inc. (Delaware)Arca

詳細

⋅ 2017年10月1日午後3時58分

Insiders bought recently before the offering at $1.10 per share. Slightly risky when Actimab-A Phase 2 results could come out anytime.